Bactoclav

Quick links to important sections

Bactoclav

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactoclav

What is Bactoclav: A Fixed-Dose Combination

Property Description
Active ingredients Amoxicillin, Clavulanic Acid
Form Tablet, Suspension, Powder for Injection
Pharmacological class Penicillin/Beta-lactamase Inhibitor Combination
Common use Treating bacterial infections
Origin Semi-synthetic

Bactoclav is a prescription-only, fixed-dose combination medicine classified as a Penicillin/Beta-lactamase Inhibitor Combination antibiotic. This drug, a semi-synthetic derivative, is clinically recognized for its utility in treating a wide array of infections, including those affecting the respiratory and urinary tracts. This specialized classification distinguishes it from standard penicillins because it incorporates a protective agent, ensuring the antibiotic's action against bacteria that have developed mechanisms of resistance. Its fundamental purpose is to fight the growth of susceptible bacterial pathogens.


Key Ingredients and Available Forms

The medication is composed of two essential active ingredients: the aminopenicillin Amoxicillin and the modifying agent Clavulanic Acid, which is commonly supplied as Potassium Clavulanate. The combination utilizes Amoxicillin, a well-established beta-lactam antibiotic, alongside the unique enzyme inhibitor Clavulanic Acid. This formulation is widely used internationally, with similar combinations also sold under brands like Augmentin. The combination is supplied across various pharmaceutical preparations to ensure flexibility in treatment, including Oral Tablets, Oral Suspension (designed for children and those who have difficulty swallowing), and Powder for Injection, allowing for administration via both the oral and intravenous routes.


Why the Combination Matters: General Purpose

The inclusion of Clavulanic Acid is vital because it acts as a protective agent against bacterial enzymes called beta-lactamases, thereby ensuring the Amoxicillin remains potent. This creates a powerful synergistic action where the two components work together to overcome common bacterial defense mechanisms. The general therapeutic purpose of this robust combination is to provide a reliable, broad-spectrum approach to treating bacterial infections by maintaining the antibiotic's potency and overcoming the issue of resistance.

Regulatory References

  1. MedlinePlus: Amoxicillin and Clavulanate
  2. PubChem Compound Summary: Amoxicillin-Clavulanic Acid

What side effects are possible with Bactoclav?

Possible Side Effects and Safety Information

Bactoclav (Amoxicillin and Clavulanate Potassium) is generally well-tolerated, but it can cause adverse reactions, primarily affecting the gastrointestinal tract and immune system. The most common side effects include diarrhea (which is very common in adults), nausea, vomiting, and mucocutaneous candidiasis (thrush).

Serious and Clinically Significant Reactions

While rare, certain reactions require immediate medical attention:

  • Severe Hypersensitivity Reactions: These include anaphylaxis, angioedema (swelling of the face, throat, or tongue), and serum sickness-like reactions. Bactoclav is contraindicated in patients with a history of allergy to penicillin or other beta-lactam antibiotics.
  • Liver Dysfunction (Hepatotoxicity): Hepatitis and cholestatic jaundice have been reported, sometimes becoming severe, especially in elderly male patients or after prolonged use. Use is contraindicated in individuals with a previous history of liver problems associated with this medication.
  • Severe Skin Reactions: Rare but serious conditions, such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), have been associated with this drug.
  • Antibiotic-Associated Colitis: Diarrhea that is watery, severe, or contains blood or mucus, potentially occurring even weeks after treatment, may indicate inflammation of the large intestine and must be reported immediately.

Safety Considerations

Cautions and Restrictions

This medication must be used with caution in patients with impaired kidney function or liver disease, as dosage adjustments or careful monitoring may be necessary. Patients with infectious mononucleosis should generally avoid this drug due to an increased risk of rash. Regular assessment of renal, hepatic, and blood cell function is recommended during prolonged therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with the Amoxicillin and Clavulanic Acid combination is defined by government regulatory documents based on specific clinical manifestations and mandated emergency actions.

Documented Manifestations and Severe Outcomes

Overdose exposure may present with gastrointestinal symptoms, including stomach pain, vomiting, and diarrhea, as well as Central Nervous System effects such as sleepiness and convulsions (seizures). The official profile notes specific renal and urinary changes, including cloudy urine and a greatly decreased amount of urine. Life-threatening outcomes documented include acute kidney failure secondary to crystalluria, severe hepatic injury, or collapse. The risk of convulsions is specifically increased in patients with impaired renal function or after receiving high doses.

Emergency Actions and Supportive Measures

Immediate medical attention is required upon recognition of overdose signs. Official instructions mandate that emergency services must be contacted immediately if the individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Since no specific antidote is known, management is symptomatic and supportive treatment. The regulatory information notes that the components of Bactoclav can be removed from the circulation by the procedure haemodialysis, and supportive care includes measures to maintain adequate fluid output.

Therapeutic Uses of Bactoclav

What Bactoclav Treats: Main Uses and Benefits

Bactoclav is a combination medication commonly used across conditions presenting with episodic or fluctuating manifestations. It is generally applied in settings that involve symptoms related to systemic imbalance and localized discomfort. This includes common indications such as infections of the respiratory tract (like community-acquired pneumonia and acute sinusitis), the urinary tract (including pyelonephritis), and skin and soft tissues (conditions where functional stability becomes affected). It is also relevant for managing symptoms related to inflammatory or irritative states.

The medication is applied in clinical settings that involve acute or unstable symptom patterns. It is used to address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

“It is commonly used to help manage the conditions presenting with acute or disruptive episodes, relevant in contexts involving heightened systemic burden.”


Quick Fact: Symptomatic Relief Domains The therapeutic use of Bactoclav supports the patient during difficult episodes by easing distress, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Bactoclav (Amoxicillin/Clavulanate) is strictly defined by regulatory authorities based on a patient’s medical status and history. This information identifies populations who are absolutely prohibited from use and those who require restricted or conditional eligibility.

Absolute Contraindications

The medicine must not be used by any individual with a history of serious hypersensitivity to any penicillin (including Amoxicillin), other beta-lactam antibiotics, or any excipient in the formulation. It is also strictly contraindicated for patients with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with Amoxicillin/Clavulanate treatment.

Eligibility Restrictions

  • Organ Function: Patients with severe renal impairment (creatinine clearance < 30 mL/min) are prohibited from using specific extended-release tablets, and standard formulations require specific dose management. Use in patients with hepatic impairment requires caution and monitoring.
  • Age: The drug is not recommended for children under 40 kg to use adult-strength tablets. Infants younger than 12 weeks require specialized, low-concentration formulations.
  • Comorbidity: The medicine should be avoided in patients with suspected Infectious Mononucleosis due to the high likelihood of a generalized rash.
  • Reproductive Status: Use during pregnancy (FDA Category B) and lactation requires caution, as the components are excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bactoclav identifies several medicinal product categories that are associated with documented interaction patterns. These interactions are categorized based on their mechanism, affecting either drug exposure or specific pharmacodynamic outcomes.

Pharmacokinetic and Exposure Alterations

Co-administration with Probenecid is not recommended in official documentation. Probenecid inhibits the renal tubular secretion of the Amoxicillin component, resulting in documented increased and prolonged plasma concentrations of Amoxicillin.

When combined with Methotrexate, Bactoclav may lead to increased Methotrexate exposure by reducing its clearance, which can result in elevated and prolonged plasma levels. Additionally, co-administration with Mycophenolate Mofetil (MMF) has been reported to reduce the trough concentration of MMF’s active metabolite, Mycophenolic Acid. The combination may also reduce the efficacy of Oral Contraceptives.

Pharmacodynamic and Administration Rules

Co-administration with Oral Anticoagulants may prolong prothrombin time and increase the International Normalized Ratio (INR); this documented pharmacodynamic effect necessitates the monitoring of coagulation parameters. The use of Allopurinol with Bactoclav is associated with an increased incidence of rash.

Regarding administration, the regulatory information specifies that to optimize the absorption of the Clavulanic Acid component and minimize potential gastrointestinal intolerance, the product should be taken at the start of a meal or snack. No specific interaction notes are documented for alcohol or herbal products.

Mechanism of Action

Bactoclav functions via a dual mechanistic approach involving enzyme inhibition and structural disruption, focusing on the distinct biochemical pathways of susceptible microorganisms.

Inhibiting Bacterial Cell Wall Synthesis

This domain describes the primary bactericidal mechanism of Amoxicillin. The compound operates by binding irreversibly to Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for the final cross-linking of the peptidoglycan layer in the bacterial cell wall. This targeted pathway interference prevents the synthesis of a structurally rigid wall, initiating a subsequent cascade that results in bacterial cell lysis and eventual loss of viability.

Neutralizing Bacterial Defense Enzymes

This domain addresses the inhibition of bacterial resistance mechanisms through Clavulanic acid. Clavulanic acid acts as a suicide inhibitor by forming a covalent bond with the active site of the beta-lactamase enzymes. These enzymes are produced by certain bacteria to hydrolyze and neutralize Amoxicillin. By irreversibly inactivating the beta-lactamases, Clavulanic acid shields the Amoxicillin component, thereby facilitating the unimpeded action of Amoxicillin and enabling the compound to exert its intended bactericidal activity against otherwise resistant strains.

Dosage and Administration Information

Bactoclav administration is governed by a structured protocol ensuring standardized usage. The medicine is approved for both Oral (tablets, suspension) and Intravenous (IV) routes, with the chosen method based on the severity of the condition and overall clinical status. Oral dosing generally follows either a twice-daily (every 12 hours) or thrice-daily (every 8 hours) frequency, corresponding to the specific dose strength prescribed.

A mandatory administration requirement is to take the oral dose at the start of a meal. This procedural step is utilized to enhance the absorption of the clavulanic acid component. Dosing is systematic, with standard adult oral regimens ranging from 500 mg/125 mg up to 875 mg/125 mg, or IV regimens of 1000 mg/200 mg every eight hours for severe cases.

An essential procedural constraint is the requirement for dose adjustment in patients with impaired renal function, particularly those with a creatinine clearance below 30 mL/min, for whom the use of high-strength tablets is not recommended. Furthermore, the total treatment course is limited to no more than 14 days without clinical reassessment. Proper preparation is also critical: oral suspensions must be shaken well before use, and extended-release tablets must be swallowed whole to preserve their release properties.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bactoclav

This section details the structure of the clinical research for Bactoclav (amoxicillin/clavulanate), outlining the type of studies conducted, the outcomes measured, and where evidence remains uncertain. This information is derived from regulatory and scientific reports and does not provide personal medical advice or treatment recommendations.


Evidence for Use in Respiratory Tract Infections

Research for infections like Community-Acquired Pneumonia (CAP) and Acute Bacterial Sinusitis primarily involves short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, often comparing the combination to other agents evaluated in the same context. Researchers monitored outcomes related to systemic status, such as hospitalization rates, and tracked the time needed for symptoms like cough or fever to be reported as resolved. These trials included cohorts of adults, older adults, and children with acute infections.

Study data describe patterns observed in research settings that included bacteria with identified resistance mechanisms. However, the evidence base still has some limitations, including that long-term effects are not fully established, particularly concerning the durability of response or patterns of recurrence several months after the treatment period.

Evidence for Use in Skin and Soft Tissue Infections

Studies examining Skin and Soft Tissue Infections (SSTIs) include both RCTs and supplementary observational studies. The measured outcomes included tracking clinical status at the infection site and monitoring the rate of subsequent change in antibiotic therapy. Research explored short-term changes by monitoring the rate of intervention or treatment escalation.

Follow-up durations were limited in many of these studies, focusing heavily on the immediate treatment period. For more severe or complex SSTIs, many studies were observational rather than randomized, which may limit the generalizability of the findings. The evidence base suggests that data for certain groups remain insufficient when looking for long-term outcomes.

What Is Still Uncertain About Bactoclav Research

The evidence base suggests that findings were mixed across various studies concerning the overall consistency of results. Comparative evidence is lacking in some areas, as some research used this drug only as a standard comparator. It has been noted that the evidence quality varies across studies regarding the comprehensive reporting of common adverse events. The research provides context, but it is important to remember that study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Amoxicillin and Clavulanate: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Bactoclav (FAQ)

Q: Does Bactoclav commonly cause diarrhea?

A: According to official product information, diarrhea or loose stools are one of the most frequent adverse reactions reported. Studies have indicated that it can affect a high percentage of both adults and children.

Q: If Bactoclav causes loose stools, is that a serious problem?

A: Common loose stools are different from severe symptoms. While loose stools are frequent, regulatory information describes severe, watery, or bloody diarrhea as a serious symptom that may indicate inflammation of the large intestine. This type of severe diarrhea is documented as needing immediate medical attention and can occur even several weeks or months after the medication is stopped.

Q: Can I drink alcohol while taking Bactoclav?

A: Official regulatory information for this medication does not document a specific drug-drug or drug-alcohol interaction with the active components. While no specific interaction is documented, individuals may wish to consider that the medication can cause dizziness or stomach upset.

Q: Are older adults more likely to have side effects from Bactoclav?

A: Regulatory documents note that older adults may be at an increased risk for certain side effects. Specifically, liver-related issues, such as hepatitis or jaundice, are reported as sometimes being severe, particularly in elderly male patients or following prolonged use.

Q: How long does Bactoclav stay in your system after the last dose?

A: Based on official pharmacokinetic data, the time the drug takes to be reduced by half (the half-life) is quite short. The half-life of Amoxicillin is described as approximately 1.3 hours, and the half-life of Clavulanic Acid is described as approximately 1.0 hour.

Q: How long until the side effects of Bactoclav go away after stopping the medicine?

A: Common side effects generally subside soon after treatment is completed. However, regulatory warnings note that a serious form of diarrhea (Colitis) may begin during or even several weeks or months after the medication is stopped. This condition is documented as needing immediate medical attention.

Q: Is it safe to take Bactoclav with common pain relievers like Tylenol or ibuprofen?

A: The official regulatory warnings for this product do not list specific interactions with common non-prescription pain relievers such as acetaminophen (Tylenol) or ibuprofen. The documented interactions are primarily with other prescription medications.

Q: Is Bactoclav considered a strong antibiotic?

A: The medication is not classified by descriptive terms such as 'strong.' It is officially described as a combination product that is reserved for treating infections caused by bacteria with certain resistance mechanisms, providing a broader spectrum of activity than Amoxicillin alone.

Q: Why is Bactoclav used for ear infections?

A: Official regulatory decisions indicate that this combination product is approved for the treatment of certain severe infections of the ear, nose, and throat. This includes conditions such as acute otitis media (a type of ear infection) and sinusitis.

Q: What is the difference between Bactoclav and plain amoxicillin?

A: The key difference is the addition of Clavulanic Acid. This component acts as a protective agent that shields the Amoxicillin from being broken down by certain bacterial defense enzymes known as beta-lactamases, allowing the antibiotic to work effectively.

Q: Does Bactoclav start working right away?

A: The concentration of the drug in the blood does not peak immediately upon swallowing. According to official pharmacokinetic data, drug concentrations typically reach their highest levels (peak) approximately 1.5 hours after a dose is taken.

Q: If I stop taking Bactoclav early, what happens?

A: Regulatory warnings indicate that not taking the full course of medication as prescribed can contribute to a public health issue: the development of drug-resistant bacteria. It may also lead to an overgrowth of other organisms.

Q: Is it normal to feel tired while taking Bactoclav?

A: The adverse reaction list includes effects like dizziness and headache as uncommon side effects. Extreme tiredness (fatigue) and weakness are also noted in the regulatory documents, sometimes in association with rare, serious reactions like liver damage.

Q: Can Bactoclav affect your sleep?

A: Official adverse event lists indicate that trouble with sleeping has been reported as a possible adverse effect. However, the exact frequency of this occurrence is not known from the available data.

Q: Is there a link between Bactoclav and yeast infections?

A: Yes. Thrush (or mucocutaneous candidiasis), which is a common type of yeast infection, is listed in the product's official documentation as a common side effect.

Q: Do foods or drinks affect how Bactoclav is absorbed?

A: Yes, regulatory documents describe an effect. Taking the medicine with food, particularly at the start of a meal, is described as enhancing the absorption of the clavulanate component compared to taking it without food.

Q: Can Bactoclav be taken on an empty stomach?

A: Official administration instructions state that the medicine may be taken without regard to meals. However, taking it at the start of a meal is recommended to enhance the absorption of the clavulanate component.

Q: Can Bactoclav be used for dental infections?

A: This combination product is used for treating a variety of infections and is sometimes utilized as a treatment alternative in certain complicated cases of dental infection.

Q: Why might a doctor prescribe Bactoclav instead of another antibiotic?

A: The primary reason for its use is the protection offered by clavulanate acid. The combination extends the drug's activity to cover certain types of bacteria that are resistant to Amoxicillin alone, which is a key reason for its selection.

Q: What are the common skin reactions associated with Bactoclav?

A: Common skin reactions reported in official documents include general rashes and hives (urticaria). These reactions are listed among the more frequently reported adverse effects in clinical studies.

Q: Can Bactoclav cause changes in mood or confusion?

A: Official adverse reaction lists include effects such as dizziness. In rare instances associated with serious reactions like severe vomiting or extreme weakness, confusion has also been noted in official reports.

Q: Is Bactoclav effective against drug-resistant bacteria?

A: Yes, the product is specifically designed to address resistance. The combination provides activity against certain strains of bacteria that produce beta-lactamase enzymes, which would make them resistant to treatment with amoxicillin alone.

Q: What is the typical length of a Bactoclav prescription?

A: The prescribed duration of treatment is specific to the type of infection being treated. Official instructions show that common courses can range from 7 to 10 days for conditions like Community-Acquired Pneumonia, or 10 days for Acute Bacterial Sinusitis.

Q: Does the form of Bactoclav (tablet vs. liquid) make a difference?

A: Yes, official documentation explicitly warns that certain tablets and suspensions are not interchangeable. This is because they can differ in the amount or ratio of active ingredients (clavulanic acid) or in the way the drug is released in the body.

Q: Do studies show Bactoclav is frequently studied in children?

A: Official documentation includes specific dosage and administration guidance for pediatric patients (including infants and children). Regulatory clinical trials have historically included cohorts of children for all approved indications.

Q: Is Bactoclav prescribed for prophylaxis (preventative use) in some cases?

A: Regulatory information notes that the medication may be considered for preventative use in specific clinical settings, such as certain complicated oral-surgical procedures.

How should Bactoclav be stored and disposed of?

How to Store and Dispose of Bactoclav

Proper storage and handling ensure medication stability and safety.

Product Form Storage Condition Handling & Disposal
Tablets (Unopened) Store at room temperature (e.g., 20 C to 25 C). Keep away from excess heat and moisture (do not store in the bathroom). Keep the container tightly closed and in its original packaging.
Oral Suspension (Reconstituted) Must be stored in the refrigerator (e.g., 2 C to 8 C). Do not freeze. Shake well before each use. Dispose of any unused liquid after 10 days.

All forms of this medication must be kept in their original, tightly closed containers, out of sight and reach of children. Always lock safety caps. Dispose of expired or unused medication according to local drug take-back programs or by mixing it with an undesirable substance and placing it in a sealed bag in the trash; do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactoclav found in:

A-Z Index: